“We are very pleased with the continued progress being made in our Hansoh Pharma collaboration,” said Craig Tooman, President and CEO of Silenc...
In addition, Melinta and BARDA will partner on the development of BAXDELA® against biothreat pathogens. Under this contract, BARDA has awarded $20.5M f...
New call for projects for treatments that could be repurposed to treat epidermolysis bullosa (EB), a life-changing and currently incurable rare skin dise...
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, de...
Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on optimizing ADC...
FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter...
INOVIQ and Promega sign a global joint marketing agreement for INOVIQ’s EXO-NET® exosome capture technology and Promega Nucleic Acid purificati...
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, de...
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced a clinical ...
Designation confers advantages including marketing exclusivity and tax credits Padeliporfin VTP Phase 1 trial in Pancreatic cancer to start b...
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeuti...
Thermo Fisher Scientific, a global leading company in science services, today announced the launch of the Gibco™ OncoPro™ tumor media kit. *, t...
In VIRAGE, the ongoing multinational Phase 2b clinical study, intravenous VCN-01 is being evaluated in combination with standard-of-care (SoC) chemotherapy...
First participants have been successfully dosed in a Phase I Clinical Trial of MAP 315, Microba’s lead Therapeutic Program in Inflammatory Bo...
© 2025 Biopharma Boardroom. All Rights Reserved.
